Auto Amazon Links: No products found.
The National Health Service (NHS) in England and Wales is now offering the first drug designed to delay the onset of type 1 diabetes. Known as teplizumab, this immunotherapy treatment can extend the period before symptoms appear and the need for lifelong insulin therapy by about three years. This development represents a significant breakthrough for many children and young people who may benefit annually.
Teplizumab works by modulating the immune system, which in type 1 diabetes mistakenly attacks the insulin-producing cells in the pancreas. Unlike type 2 diabetes, typically linked to factors such as weight, type 1 diabetes requires careful management of blood sugar levels through insulin injections or pumps. The drug must be administered via an infusion over 14 consecutive days before symptoms begin, and patients require preceding blood tests to confirm that their immune system is already targeting pancreatic cells.
The impact of this new treatment is seen as profound by patient advocacy groups. Karen Addington, chief executive of the charity Breakthrough T1D, emphasized the emotional importance of the drug, stating, “If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition.” For families like the Sebastian-Jenkins, whose son Theo was diagnosed at four, managing the disease involves constant vigilance—including monitoring carbohydrate intake and blood glucose levels to avoid dangerous highs or lows. Although Theo was too young to receive teplizumab, his parents recognize the potential relief it could offer others by providing extra years free from the disease’s daily challenges.
Another example is Dima Boichak from Newbury, who was among the first in the UK to receive teplizumab on compassionate grounds after participating in a nationwide research study. Dima’s mother, Elena, described the treatment’s two-week regimen as “hard work” but invaluable, expressing hope that the drug would allow her son more “time being a normal kid, living a normal life.” The National Institute for Health and Care Excellence (NICE), which has recommended the drug, estimates that over a thousand adults and children could be eligible in its initial year, with around 820 receiving it annually afterward once demand levels out. However, teplizumab’s availability across the UK varies, with separate decision-making bodies in Scotland and Northern Ireland, and ongoing discussions about expanding routine screening in the UK to identify those at risk earlier
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.